Oxaliplatin: a review of preclinical and clinical studies. (Q54114691)

24 May 2018

review article

1 reference

title

Oxaliplatin: a review of preclinical and clinical studies. (English)

1 reference

24 May 2018

1 reference

E Raymond

1 reference

24 May 2018

S G Chaney

series ordinal

1 reference

24 May 2018

A Taamma

series ordinal

1 reference

24 May 2018

E Cvitkovic

series ordinal

1 reference

24 May 2018

publication date

1 October 1998

1 reference

24 May 2018

published in

Annals of Oncology

1 reference

24 May 2018

volume

1 reference

24 May 2018

issue

1 reference

24 May 2018

page(s)

1053-1071

1 reference

24 May 2018

New platinum complexes with anti-tumour activity

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Displacement of the bidentate malonate ligand from (d,l-trans-1,2-diaminocyclohexane)malonatoplatinum(II)by physiologically important compounds in vitro

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Kinetics of the reaction of cis-platinum compounds with DNA in vitro

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Kinetic investigation of the DNA platination reaction: evidence for a transient adduct between deoxyribonucleic acid and cis-platinum(II).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

An information-intensive approach to the molecular pharmacology of cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Intracellular glutathione and cytotoxicity of platinum complexes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Antitumor activity of l-OHP in mice.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Synergistic action of high-dose hydroxyurea when used with cyglophosphamide and certain new organoplatinum complexes in treatment of advanced L1210 leukemia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Overexpression of metallothionein confers resistance to anticancer drugs.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Nucleotide excision repair

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Evaluation of inductively coupled mass spectrometry for the determination of platinum in plasma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Transcription-coupled repair deficiency and mutations in human mismatch repair genes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Genetic instability in colorectal cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008213732429

7 January 2021

Identifiers

DOI

10.1023/A:1008213732429

1 reference

24 May 2018

1 reference

24 May 2018